Discover and read the best of Twitter Threads about #CPDD22
Most recents (3)
At the #CPDD22 mini-symposium on #gabapentin talks about considerable research highlighting potential for SUD treatment but also high rates of identification in overdose. Prescribing continues to increase yet diversion appears to trend down after regulatory changes 1/
2/ anecdotal reports of #gabapentin enhancing opioid effects and reducing withdrawal. Motivation for use is a mix of non-medical use with other substances and therapeutic motivations e.g. to self manage pain/withdrawal
3/ increases in gapabentin increase in a linear manner compared with low/stable pregabalin prescribing (interesting this is reversed in Australia) - it is commonly being prescribed off label for substance use treatment
Really important study being presented by Staci Gruber at #CPDD22 which longitudinally assesses a whole range of functioning in cannabis naive ppl before and following use of medical cannabis (now 3 years of follow up funded) 1/ 
2/ most interested in use for pain, detailed info collected on cannabinoid use..including developing the cannacount metric to measure cannabinoid use
Most are using CBD dominant products, which include a range of other minor cannabinoids including CBG and CBC
David Ledgerwood talks about a pharmacist delivered contingency management in people with HIV who smoke - and of course I am super excited to see #pharmacists deliver these interventions #cpdd22 1/
2/ can pharmacists be trained to deliver contingency management for smoking cessation?
3/ yes! Of course they can. Pharmacists do really well in terms of delivering contingency management, especially discussing smoking and praising efforts and being generally skilful in smoking cessation
